Therapeutic effects of oral NADH on the symptoms of patients with CFS

1 Star2 Stars3 Stars4 Stars5 Stars (47 votes, average: 3.05 out of 5)

BACKGROUND: Chronic fatigue syndrome (CFS) is a disorder of

unknown etiology, consisting of prolonged, debilitating

fatigue, and a multitude of symptoms including neurocognitive

dysfunction, flu-like symptoms, myalgia, weakness, arthralgia,

low-grade fever, sore throat, headache, sleep disturbances,

and swelling and tenderness of lymph nodes. No effective

treatment for CFS is known.

OBJECTIVE: The purpose of the

study was to evaluate the efficacy of the reduced form of

nicotinamide adenine dinucleotide (NADH) i.e., ENADA the

stabilized oral absorbable form, in a randomized,

double-blind, placebo-controlled crossover study in patients

with CFS. Nicotinamide adenine dinucleotide is known to

trigger energy production through ATP generation which may

form the basis of its potential effects.

METHODS: Twenty-six

eligible patients who fulfilled the Center for Disease Control

and Prevention criteria for CFS completed the study. Medical

history, physical examination, laboratory studies, and

questionnaire were obtained at baseline, 4, 8, and 12 weeks.

Subjects were randomly assigned to receive either 10 mg of

NADH or placebo for a 4-week period. Following a 4-week

washout period, subjects were crossed to the alternate regimen

for a final 4-week period.

RESULTS: No severe adverse effects

were observed related to the study drug. Within this cohort of

26 patients, 8 of 26 (31%) responded favorably to NADH in

contrast to 2 of 26 (8%) to placebo. Based upon these

encouraging results we have decided to conduct an open-label

study in a larger cohort of patients.


Collectively, the results of this pilot study indicate that

NADH may be a valuable adjunctive therapy in the management of

the chronic fatigue syndrome and suggest that further clinical

trials be performed to establish its efficacy in this

clinically perplexing disorder.

Forsyth LM, Preuss HG, MacDowell AL, Chiazze L Jr, Birkmayer GD,

Bellanti JA

1 Star2 Stars3 Stars4 Stars5 Stars (47 votes, average: 3.05 out of 5)

Leave a Reply